nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—mammary gland—lung cancer	0.0419	0.184	CbGeAlD
Fluocinonide—SMO—respiratory system—lung cancer	0.0279	0.123	CbGeAlD
Fluocinonide—SMO—bronchus—lung cancer	0.023	0.101	CbGeAlD
Fluocinonide—SMO—trachea—lung cancer	0.0206	0.0906	CbGeAlD
Fluocinonide—SMO—cardiac atrium—lung cancer	0.0194	0.0851	CbGeAlD
Fluocinonide—Dermatitis acneiform—Erlotinib—lung cancer	0.0164	0.0394	CcSEcCtD
Fluocinonide—SERPINA6—respiratory system—lung cancer	0.0154	0.0675	CbGeAlD
Fluocinonide—Eruption—Gefitinib—lung cancer	0.0153	0.0366	CcSEcCtD
Fluocinonide—SMO—lung—lung cancer	0.0148	0.0651	CbGeAlD
Fluocinonide—SMO—lymph node—lung cancer	0.0101	0.0445	CbGeAlD
Fluocinonide—Skin exfoliation—Pemetrexed—lung cancer	0.00902	0.0216	CcSEcCtD
Fluocinonide—SERPINA6—bone marrow—lung cancer	0.009	0.0396	CbGeAlD
Fluocinonide—Folliculitis—Erlotinib—lung cancer	0.00893	0.0214	CcSEcCtD
Fluocinonide—Telangiectasia—Methotrexate—lung cancer	0.00846	0.0203	CcSEcCtD
Fluocinonide—SERPINA6—lung—lung cancer	0.00816	0.0358	CbGeAlD
Fluocinonide—Amcinonide—ANXA1—lung cancer	0.00787	0.432	CrCbGaD
Fluocinonide—NR3C1—respiratory system—lung cancer	0.00673	0.0296	CbGeAlD
Fluocinonide—Eruption—Gemcitabine—lung cancer	0.00634	0.0152	CcSEcCtD
Fluocinonide—Dry skin—Gefitinib—lung cancer	0.00625	0.015	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—lung cancer	0.00587	0.0141	CcSEcCtD
Fluocinonide—NR3C1—epithelium—lung cancer	0.00562	0.0247	CbGeAlD
Fluocinonide—NR3C1—bronchus—lung cancer	0.00554	0.0243	CbGeAlD
Fluocinonide—Skin exfoliation—Erlotinib—lung cancer	0.00536	0.0128	CcSEcCtD
Fluocinonide—Folliculitis—Paclitaxel—lung cancer	0.00519	0.0125	CcSEcCtD
Fluocinonide—NR3C1—trachea—lung cancer	0.00497	0.0218	CbGeAlD
Fluocinonide—Leukoderma—Methotrexate—lung cancer	0.00469	0.0112	CcSEcCtD
Fluocinonide—NR3C1—cardiac atrium—lung cancer	0.00467	0.0205	CbGeAlD
Fluocinonide—Skin exfoliation—Vinorelbine—lung cancer	0.00463	0.0111	CcSEcCtD
Fluocinonide—Eruption—Docetaxel—lung cancer	0.0045	0.0108	CcSEcCtD
Fluocinonide—Erythema—Pemetrexed—lung cancer	0.00413	0.00991	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—lung cancer	0.00406	0.00974	CcSEcCtD
Fluocinonide—NR3C1—bone marrow—lung cancer	0.00394	0.0173	CbGeAlD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Crizotinib—lung cancer	0.00382	0.00916	CcSEcCtD
Fluocinonide—Dry skin—Erlotinib—lung cancer	0.00373	0.00896	CcSEcCtD
Fluocinonide—Skin exfoliation—Gemcitabine—lung cancer	0.00372	0.00893	CcSEcCtD
Fluocinonide—Infection—Crizotinib—lung cancer	0.00366	0.00879	CcSEcCtD
Fluocinonide—Nervous system disorder—Crizotinib—lung cancer	0.00362	0.00868	CcSEcCtD
Fluocinonide—Skin disorder—Crizotinib—lung cancer	0.00358	0.00859	CcSEcCtD
Fluocinonide—NR3C1—lung—lung cancer	0.00357	0.0157	CbGeAlD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.00349	0.00837	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.00347	0.00832	CcSEcCtD
Fluocinonide—Skin exfoliation—Cisplatin—lung cancer	0.00347	0.00832	CcSEcCtD
Fluocinonide—Infection—Pemetrexed—lung cancer	0.00335	0.00803	CcSEcCtD
Fluocinonide—Infection—Gefitinib—lung cancer	0.00333	0.00798	CcSEcCtD
Fluocinonide—Nervous system disorder—Pemetrexed—lung cancer	0.00331	0.00793	CcSEcCtD
Fluocinonide—Nervous system disorder—Gefitinib—lung cancer	0.00328	0.00788	CcSEcCtD
Fluocinonide—Skin disorder—Pemetrexed—lung cancer	0.00327	0.00785	CcSEcCtD
Fluocinonide—Skin disorder—Gefitinib—lung cancer	0.00325	0.0078	CcSEcCtD
Fluocinonide—Eruption—Methotrexate—lung cancer	0.00324	0.00777	CcSEcCtD
Fluocinonide—Skin exfoliation—Etoposide—lung cancer	0.00318	0.00762	CcSEcCtD
Fluocinonide—Folliculitis—Methotrexate—lung cancer	0.00317	0.00761	CcSEcCtD
Fluocinonide—Skin exfoliation—Paclitaxel—lung cancer	0.00312	0.00747	CcSEcCtD
Fluocinonide—Nasal congestion—Cisplatin—lung cancer	0.00289	0.00694	CcSEcCtD
Fluocinonide—Pain—Pemetrexed—lung cancer	0.00288	0.00691	CcSEcCtD
Fluocinonide—Pain—Gefitinib—lung cancer	0.00286	0.00687	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—lung cancer	0.00281	0.00673	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—lung cancer	0.00275	0.00659	CcSEcCtD
Fluocinonide—Swelling—Etoposide—lung cancer	0.00274	0.00657	CcSEcCtD
Fluocinonide—Infection—Teniposide—lung cancer	0.00271	0.00651	CcSEcCtD
Fluocinonide—Swelling—Paclitaxel—lung cancer	0.00268	0.00644	CcSEcCtD
Fluocinonide—Skin exfoliation—Docetaxel—lung cancer	0.00264	0.00633	CcSEcCtD
Fluocinonide—Nasal congestion—Paclitaxel—lung cancer	0.0026	0.00624	CcSEcCtD
Fluocinonide—Immune system disorder—Topotecan—lung cancer	0.00257	0.00617	CcSEcCtD
Fluocinonide—Hypersensitivity—Pemetrexed—lung cancer	0.00248	0.00596	CcSEcCtD
Fluocinonide—Dexamethasone—ANXA1—lung cancer	0.00247	0.136	CrCbGaD
Fluocinonide—Hypersensitivity—Gefitinib—lung cancer	0.00247	0.00592	CcSEcCtD
Fluocinonide—Erythema—Erlotinib—lung cancer	0.00245	0.00588	CcSEcCtD
Fluocinonide—NR3C1—lymph node—lung cancer	0.00244	0.0107	CbGeAlD
Fluocinonide—Dizziness—Crizotinib—lung cancer	0.00244	0.00585	CcSEcCtD
Fluocinonide—Pruritus—Pemetrexed—lung cancer	0.00238	0.00572	CcSEcCtD
Fluocinonide—Pruritus—Gefitinib—lung cancer	0.00237	0.00568	CcSEcCtD
Fluocinonide—Nasopharyngitis—Cisplatin—lung cancer	0.00236	0.00566	CcSEcCtD
Fluocinonide—Rash—Crizotinib—lung cancer	0.00233	0.00558	CcSEcCtD
Fluocinonide—Dermatitis—Crizotinib—lung cancer	0.00232	0.00557	CcSEcCtD
Fluocinonide—Swelling—Docetaxel—lung cancer	0.00228	0.00546	CcSEcCtD
Fluocinonide—Dizziness—Pemetrexed—lung cancer	0.00223	0.00535	CcSEcCtD
Fluocinonide—Hyperglycaemia—Gemcitabine—lung cancer	0.00221	0.00529	CcSEcCtD
Fluocinonide—Immune system disorder—Vinorelbine—lung cancer	0.0022	0.00528	CcSEcCtD
Fluocinonide—Dry skin—Paclitaxel—lung cancer	0.00217	0.00521	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—lung cancer	0.00213	0.00511	CcSEcCtD
Fluocinonide—Rash—Pemetrexed—lung cancer	0.00212	0.0051	CcSEcCtD
Fluocinonide—Dermatitis—Pemetrexed—lung cancer	0.00212	0.00509	CcSEcCtD
Fluocinonide—Erythema—Vinorelbine—lung cancer	0.00212	0.00509	CcSEcCtD
Fluocinonide—Nasopharyngitis—Paclitaxel—lung cancer	0.00212	0.00508	CcSEcCtD
Fluocinonide—Rash—Gefitinib—lung cancer	0.00211	0.00506	CcSEcCtD
Fluocinonide—Dermatitis—Gefitinib—lung cancer	0.00211	0.00506	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.0021	0.00503	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAP2K1—lung cancer	0.00208	0.00617	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.00207	0.00497	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—SOX2—lung cancer	0.00206	0.00611	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ABCB1—lung cancer	0.00204	0.00604	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—NPPA—lung cancer	0.00201	0.00597	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Teniposide—lung cancer	0.00201	0.00482	CcSEcCtD
Fluocinonide—Infection—Topotecan—lung cancer	0.00201	0.00482	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TYMS—lung cancer	0.002	0.00594	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—OXTR—lung cancer	0.00199	0.0059	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—GRP—lung cancer	0.00199	0.0059	CbGpPWpGaD
Fluocinonide—Infection—Erlotinib—lung cancer	0.00199	0.00477	CcSEcCtD
Fluocinonide—Nervous system disorder—Topotecan—lung cancer	0.00198	0.00476	CcSEcCtD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—AVP—lung cancer	0.00198	0.00586	CbGpPWpGaD
Fluocinonide—Skin disorder—Topotecan—lung cancer	0.00197	0.00471	CcSEcCtD
Fluocinonide—Nervous system disorder—Erlotinib—lung cancer	0.00196	0.00471	CcSEcCtD
Fluocinonide—Skin disorder—Erlotinib—lung cancer	0.00194	0.00466	CcSEcCtD
Fluocinonide—Pruritus—Teniposide—lung cancer	0.00193	0.00463	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—ATF3—lung cancer	0.00191	0.00566	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Methotrexate—lung cancer	0.0019	0.00457	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—GNG11—lung cancer	0.00186	0.00552	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Paclitaxel—lung cancer	0.00185	0.00443	CcSEcCtD
Fluocinonide—Dry skin—Docetaxel—lung cancer	0.00184	0.00441	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—FASLG—lung cancer	0.00184	0.00545	CbGpPWpGaD
Fluocinonide—Immune system disorder—Irinotecan—lung cancer	0.00181	0.00435	CcSEcCtD
Fluocinonide—Nasopharyngitis—Docetaxel—lung cancer	0.0018	0.00431	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00179	0.0043	CcSEcCtD
Fluocinonide—Pain—Vinblastine—lung cancer	0.00178	0.00427	CcSEcCtD
Fluocinonide—Immune system disorder—Gemcitabine—lung cancer	0.00177	0.00424	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—PTHLH—lung cancer	0.00175	0.0052	CbGpPWpGaD
Fluocinonide—Pain—Topotecan—lung cancer	0.00173	0.00415	CcSEcCtD
Fluocinonide—Rash—Teniposide—lung cancer	0.00172	0.00413	CcSEcCtD
Fluocinonide—Dermatitis—Teniposide—lung cancer	0.00172	0.00412	CcSEcCtD
Fluocinonide—Infection—Vinorelbine—lung cancer	0.00172	0.00412	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—SFN—lung cancer	0.00172	0.0051	CbGpPWpGaD
Fluocinonide—Pain—Erlotinib—lung cancer	0.00171	0.00411	CcSEcCtD
Fluocinonide—Headache—Teniposide—lung cancer	0.00171	0.0041	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—lung cancer	0.00171	0.00409	CcSEcCtD
Fluocinonide—Erythema—Gemcitabine—lung cancer	0.0017	0.00409	CcSEcCtD
Fluocinonide—Nervous system disorder—Vinorelbine—lung cancer	0.0017	0.00407	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ATF3—lung cancer	0.0017	0.00503	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—FGFR1—lung cancer	0.00169	0.00502	CbGpPWpGaD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—AKT1—lung cancer	0.00169	0.00502	CbGpPWpGaD
Fluocinonide—Skin disorder—Vinorelbine—lung cancer	0.00168	0.00403	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—lung cancer	0.00165	0.00395	CcSEcCtD
Fluocinonide—Immune system disorder—Cisplatin—lung cancer	0.00165	0.00395	CcSEcCtD
Fluocinonide—Erythema—Cisplatin—lung cancer	0.00159	0.00381	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—SMARCA4—lung cancer	0.00158	0.00469	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—APP—lung cancer	0.00156	0.00463	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—PTHLH—lung cancer	0.00156	0.00462	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Vinblastine—lung cancer	0.00153	0.00368	CcSEcCtD
Fluocinonide—Immune system disorder—Etoposide—lung cancer	0.00151	0.00362	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.00151	0.00446	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Topotecan—lung cancer	0.00149	0.00358	CcSEcCtD
Fluocinonide—Pain—Vinorelbine—lung cancer	0.00148	0.00355	CcSEcCtD
Fluocinonide—Immune system disorder—Paclitaxel—lung cancer	0.00148	0.00355	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IRF1—lung cancer	0.00148	0.00438	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—APC—lung cancer	0.00147	0.00436	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—ANXA1—lung cancer	0.00146	0.00434	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—GIPR—lung cancer	0.00146	0.00433	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGF—lung cancer	0.00145	0.00431	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—JUNB—lung cancer	0.00145	0.00429	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00144	0.00346	CcSEcCtD
Fluocinonide—NR3C1—Circadian Clock—AVP—lung cancer	0.00144	0.00427	CbGpPWpGaD
Fluocinonide—Pruritus—Topotecan—lung cancer	0.00143	0.00343	CcSEcCtD
Fluocinonide—Erythema—Paclitaxel—lung cancer	0.00143	0.00342	CcSEcCtD
Fluocinonide—Clobetasol propionate—CYP1A1—lung cancer	0.00142	0.0779	CrCbGaD
Fluocinonide—Infection—Irinotecan—lung cancer	0.00142	0.0034	CcSEcCtD
Fluocinonide—Pruritus—Erlotinib—lung cancer	0.00142	0.0034	CcSEcCtD
Fluocinonide—Nervous system disorder—Irinotecan—lung cancer	0.0014	0.00336	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—APP—lung cancer	0.00139	0.00412	CbGpPWpGaD
Fluocinonide—Infection—Gemcitabine—lung cancer	0.00138	0.00331	CcSEcCtD
Fluocinonide—Dizziness—Vinblastine—lung cancer	0.00138	0.0033	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CASP8—lung cancer	0.00137	0.00406	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Gemcitabine—lung cancer	0.00136	0.00327	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CREBBP—lung cancer	0.00136	0.00404	CbGpPWpGaD
Fluocinonide—Skin disorder—Gemcitabine—lung cancer	0.00135	0.00324	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.00134	0.00322	CcSEcCtD
Fluocinonide—Dizziness—Topotecan—lung cancer	0.00134	0.00321	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—lung cancer	0.00133	0.00395	CbGpPWpGaD
Fluocinonide—Dizziness—Erlotinib—lung cancer	0.00132	0.00318	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—APOA1—lung cancer	0.00132	0.0039	CbGpPWpGaD
Fluocinonide—Headache—Vinblastine—lung cancer	0.0013	0.00313	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAP2K1—lung cancer	0.0013	0.00386	CbGpPWpGaD
Fluocinonide—Infection—Cisplatin—lung cancer	0.00129	0.00309	CcSEcCtD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—lung cancer	0.00128	0.00379	CbGpPWpGaD
Fluocinonide—Rash—Topotecan—lung cancer	0.00128	0.00306	CcSEcCtD
Fluocinonide—Hypersensitivity—Vinorelbine—lung cancer	0.00128	0.00306	CcSEcCtD
Fluocinonide—Dermatitis—Topotecan—lung cancer	0.00127	0.00306	CcSEcCtD
Fluocinonide—Nervous system disorder—Cisplatin—lung cancer	0.00127	0.00305	CcSEcCtD
Fluocinonide—Headache—Topotecan—lung cancer	0.00127	0.00304	CcSEcCtD
Fluocinonide—Rash—Erlotinib—lung cancer	0.00126	0.00303	CcSEcCtD
Fluocinonide—Dermatitis—Erlotinib—lung cancer	0.00126	0.00302	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—AHR—lung cancer	0.00126	0.00373	CbGpPWpGaD
Fluocinonide—Skin disorder—Cisplatin—lung cancer	0.00126	0.00302	CcSEcCtD
Fluocinonide—Immune system disorder—Docetaxel—lung cancer	0.00125	0.00301	CcSEcCtD
Fluocinonide—Headache—Erlotinib—lung cancer	0.00125	0.00301	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—GRM8—lung cancer	0.00124	0.00368	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00123	0.00295	CcSEcCtD
Fluocinonide—Pruritus—Vinorelbine—lung cancer	0.00122	0.00294	CcSEcCtD
Fluocinonide—Pain—Irinotecan—lung cancer	0.00122	0.00293	CcSEcCtD
Fluocinonide—Erythema—Docetaxel—lung cancer	0.00121	0.0029	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.00121	0.00289	CcSEcCtD
Fluocinonide—Pain—Gemcitabine—lung cancer	0.00119	0.00285	CcSEcCtD
Fluocinonide—Infection—Etoposide—lung cancer	0.00118	0.00283	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	0.00116	0.00343	CbGpPWpGaD
Fluocinonide—Infection—Paclitaxel—lung cancer	0.00116	0.00277	CcSEcCtD
Fluocinonide—Skin disorder—Etoposide—lung cancer	0.00115	0.00277	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	0.00115	0.00342	CbGpPWpGaD
Fluocinonide—Dry skin—Doxorubicin—lung cancer	0.00115	0.00275	CcSEcCtD
Fluocinonide—Dizziness—Vinorelbine—lung cancer	0.00114	0.00275	CcSEcCtD
Fluocinonide—Nervous system disorder—Paclitaxel—lung cancer	0.00114	0.00274	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.00114	0.00338	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	0.00114	0.00338	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—HIF1A—lung cancer	0.00114	0.00338	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AXL—lung cancer	0.00114	0.00337	CbGpPWpGaD
Fluocinonide—Skin disorder—Paclitaxel—lung cancer	0.00113	0.00271	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO3—lung cancer	0.00113	0.00334	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Doxorubicin—lung cancer	0.00112	0.00269	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL10—lung cancer	0.00112	0.00331	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—lung cancer	0.00112	0.00331	CbGpPWpGaD
Fluocinonide—Pain—Cisplatin—lung cancer	0.00111	0.00266	CcSEcCtD
Fluocinonide—Rash—Vinorelbine—lung cancer	0.00109	0.00262	CcSEcCtD
Fluocinonide—Dermatitis—Vinorelbine—lung cancer	0.00109	0.00262	CcSEcCtD
Fluocinonide—Headache—Vinorelbine—lung cancer	0.00108	0.0026	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—AVP—lung cancer	0.00108	0.0032	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—SOX2—lung cancer	0.00106	0.00315	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Irinotecan—lung cancer	0.00105	0.00252	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—LMNA—lung cancer	0.00104	0.00309	CbGpPWpGaD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALB—lung cancer	0.00104	0.00309	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	0.00104	0.00307	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.00103	0.00305	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.00102	0.00245	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—OXTR—lung cancer	0.00102	0.00303	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—GRP—lung cancer	0.00102	0.00303	CbGpPWpGaD
Fluocinonide—Pain—Etoposide—lung cancer	0.00102	0.00244	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	0.00101	0.00299	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	0.00101	0.00298	CbGpPWpGaD
Fluocinonide—Pain—Paclitaxel—lung cancer	0.000996	0.00239	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—lung cancer	0.000993	0.00294	CbGpPWpGaD
Fluocinonide—Pruritus—Gemcitabine—lung cancer	0.000984	0.00236	CcSEcCtD
Fluocinonide—Infection—Docetaxel—lung cancer	0.00098	0.00235	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—lung cancer	0.000977	0.00234	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	0.000975	0.00289	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	0.000973	0.00288	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Docetaxel—lung cancer	0.000968	0.00232	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—lung cancer	0.00096	0.00285	CbGpPWpGaD
Fluocinonide—Skin disorder—Docetaxel—lung cancer	0.000958	0.0023	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—GNG11—lung cancer	0.000956	0.00283	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Cisplatin—lung cancer	0.000955	0.00229	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—MMP1—lung cancer	0.000949	0.00281	CbGpPWpGaD
Fluocinonide—Dizziness—Irinotecan—lung cancer	0.000944	0.00226	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—HIF1A—lung cancer	0.000941	0.00279	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—CREBBP—lung cancer	0.000932	0.00276	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	0.000928	0.00275	CbGpPWpGaD
Fluocinonide—Immune system disorder—Methotrexate—lung cancer	0.000904	0.00217	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	0.000902	0.00268	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TF—lung cancer	0.000902	0.00267	CbGpPWpGaD
Fluocinonide—Rash—Irinotecan—lung cancer	0.0009	0.00216	CcSEcCtD
Fluocinonide—Dermatitis—Irinotecan—lung cancer	0.000899	0.00216	CcSEcCtD
Fluocinonide—Headache—Irinotecan—lung cancer	0.000894	0.00215	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—COL4A2—lung cancer	0.000884	0.00262	CbGpPWpGaD
Fluocinonide—Fluticasone furoate—ABCB1—lung cancer	0.000882	0.0484	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	0.000879	0.00261	CbGpPWpGaD
Fluocinonide—Rash—Gemcitabine—lung cancer	0.000877	0.0021	CcSEcCtD
Fluocinonide—Dermatitis—Gemcitabine—lung cancer	0.000876	0.0021	CcSEcCtD
Fluocinonide—Hypersensitivity—Etoposide—lung cancer	0.000875	0.0021	CcSEcCtD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—lung cancer	0.000872	0.00258	CbGpPWpGaD
Fluocinonide—Erythema—Methotrexate—lung cancer	0.000871	0.00209	CcSEcCtD
Fluocinonide—Headache—Gemcitabine—lung cancer	0.000871	0.00209	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—lung cancer	0.000865	0.00257	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GIPR—lung cancer	0.000862	0.00256	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—ADCY1—lung cancer	0.00086	0.00255	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Paclitaxel—lung cancer	0.000858	0.00206	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—APC—lung cancer	0.000848	0.00251	CbGpPWpGaD
Fluocinonide—Pain—Docetaxel—lung cancer	0.000844	0.00202	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—lung cancer	0.00084	0.00202	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PPP2R1B—lung cancer	0.000838	0.00248	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MMP1—lung cancer	0.000836	0.00248	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	0.000831	0.00246	CbGpPWpGaD
Fluocinonide—Pruritus—Paclitaxel—lung cancer	0.000824	0.00198	CcSEcCtD
Fluocinonide—Rash—Cisplatin—lung cancer	0.000817	0.00196	CcSEcCtD
Fluocinonide—Dermatitis—Cisplatin—lung cancer	0.000816	0.00196	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—MDM2—lung cancer	0.000815	0.00242	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	0.000809	0.0024	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SDC4—lung cancer	0.000805	0.00239	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PTHLH—lung cancer	0.000799	0.00237	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	0.000791	0.00234	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—DUSP3—lung cancer	0.000788	0.00234	CbGpPWpGaD
Fluocinonide—Dizziness—Etoposide—lung cancer	0.000785	0.00188	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—lung cancer	0.000783	0.00188	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—RHEB—lung cancer	0.000773	0.00229	CbGpPWpGaD
Fluocinonide—Dizziness—Paclitaxel—lung cancer	0.00077	0.00185	CcSEcCtD
Fluocinonide—Dexamethasone—CYP2A6—lung cancer	0.000759	0.0416	CrCbGaD
Fluocinonide—Erythema—Doxorubicin—lung cancer	0.000755	0.00181	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—ANXA1—lung cancer	0.000752	0.00223	CbGpPWpGaD
Fluocinonide—Rash—Etoposide—lung cancer	0.000749	0.0018	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—lung cancer	0.000748	0.00179	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	0.000747	0.00221	CbGpPWpGaD
Fluocinonide—Headache—Etoposide—lung cancer	0.000744	0.00178	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000737	0.00177	CcSEcCtD
Fluocinonide—Rash—Paclitaxel—lung cancer	0.000734	0.00176	CcSEcCtD
Fluocinonide—Dermatitis—Paclitaxel—lung cancer	0.000733	0.00176	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—GRM8—lung cancer	0.000733	0.00217	CbGpPWpGaD
Fluocinonide—Headache—Paclitaxel—lung cancer	0.000729	0.00175	CcSEcCtD
Fluocinonide—Hypersensitivity—Docetaxel—lung cancer	0.000727	0.00174	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—POMC—lung cancer	0.000717	0.00213	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—APP—lung cancer	0.000712	0.00211	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SKI—lung cancer	0.00071	0.0021	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—JUN—lung cancer	0.000709	0.0021	CbGpPWpGaD
Fluocinonide—Infection—Methotrexate—lung cancer	0.000707	0.00169	CcSEcCtD
Fluocinonide—Methylprednisolone—ABCB1—lung cancer	0.000703	0.0386	CrCbGaD
Fluocinonide—Pruritus—Docetaxel—lung cancer	0.000698	0.00167	CcSEcCtD
Fluocinonide—Triamcinolone—PTGS2—lung cancer	0.000698	0.0383	CrCbGaD
Fluocinonide—Nervous system disorder—Methotrexate—lung cancer	0.000697	0.00167	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—POMC—lung cancer	0.000695	0.00206	CbGpPWpGaD
Fluocinonide—Skin disorder—Methotrexate—lung cancer	0.000691	0.00166	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	0.000686	0.00203	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—lung cancer	0.000684	0.00203	CbGpPWpGaD
Fluocinonide—Dexamethasone—ABCG2—lung cancer	0.000679	0.0372	CrCbGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—lung cancer	0.000677	0.00201	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN2A—lung cancer	0.000673	0.002	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	0.000664	0.00197	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—EP300—lung cancer	0.000654	0.00194	CbGpPWpGaD
Fluocinonide—Dizziness—Docetaxel—lung cancer	0.000653	0.00157	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000638	0.00153	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—SRC—lung cancer	0.000636	0.00188	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—EP300—lung cancer	0.000635	0.00188	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—AVP—lung cancer	0.000625	0.00185	CbGpPWpGaD
Fluocinonide—Rash—Docetaxel—lung cancer	0.000622	0.00149	CcSEcCtD
Fluocinonide—Dermatitis—Docetaxel—lung cancer	0.000622	0.00149	CcSEcCtD
Fluocinonide—Headache—Docetaxel—lung cancer	0.000618	0.00148	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PXN—lung cancer	0.000616	0.00183	CbGpPWpGaD
Fluocinonide—Infection—Doxorubicin—lung cancer	0.000612	0.00147	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—CXCL8—lung cancer	0.00061	0.00181	CbGpPWpGaD
Fluocinonide—Pain—Methotrexate—lung cancer	0.000608	0.00146	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—lung cancer	0.000604	0.00145	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—GRP—lung cancer	0.000603	0.00179	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKR1C1—lung cancer	0.000603	0.00179	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—OXTR—lung cancer	0.000603	0.00179	CbGpPWpGaD
Fluocinonide—Skin disorder—Doxorubicin—lung cancer	0.000598	0.00143	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—HES1—lung cancer	0.000591	0.00175	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL10—lung cancer	0.000588	0.00174	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL2—lung cancer	0.000583	0.00173	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—lung cancer	0.000575	0.0017	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—HIF1A—lung cancer	0.000573	0.0017	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—SKI—lung cancer	0.000573	0.0017	CbGpPWpGaD
Fluocinonide—Betamethasone—PTGS2—lung cancer	0.000571	0.0313	CrCbGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CCND1—lung cancer	0.000569	0.00169	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—JUN—lung cancer	0.000567	0.00168	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GNG11—lung cancer	0.000565	0.00167	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	0.000561	0.00166	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—CXCL8—lung cancer	0.000555	0.00165	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AVP—lung cancer	0.000554	0.00164	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MMP9—lung cancer	0.000552	0.00164	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—PTEN—lung cancer	0.000549	0.00163	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP2E1—lung cancer	0.000539	0.0296	CrCbGaD
Fluocinonide—SMO—Signaling Pathways—VEGFC—lung cancer	0.000538	0.00159	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—lung cancer	0.000538	0.00159	CbGpPWpGaD
Fluocinonide—Dexamethasone—CYP1A1—lung cancer	0.000532	0.0292	CrCbGaD
Fluocinonide—Pain—Doxorubicin—lung cancer	0.000527	0.00126	CcSEcCtD
Fluocinonide—Hypersensitivity—Methotrexate—lung cancer	0.000524	0.00126	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—EP300—lung cancer	0.000523	0.00155	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—lung cancer	0.000514	0.00152	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ADCY1—lung cancer	0.000508	0.00151	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—lung cancer	0.000505	0.0015	CbGpPWpGaD
Fluocinonide—Pruritus—Methotrexate—lung cancer	0.000503	0.00121	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—JUN—lung cancer	0.0005	0.00148	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EIF2B4—lung cancer	0.000496	0.00147	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—HIF1A—lung cancer	0.000495	0.00147	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PPP2R1B—lung cancer	0.000495	0.00147	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SMARCA4—lung cancer	0.000495	0.00147	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—lung cancer	0.000489	0.00145	CbGpPWpGaD
Fluocinonide—Betamethasone—ABCB1—lung cancer	0.000486	0.0266	CrCbGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—lung cancer	0.000485	0.00144	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HSPB1—lung cancer	0.000478	0.00142	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTHLH—lung cancer	0.000472	0.0014	CbGpPWpGaD
Fluocinonide—Dizziness—Methotrexate—lung cancer	0.00047	0.00113	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—RB1—lung cancer	0.000467	0.00138	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—lung cancer	0.000466	0.00138	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—lung cancer	0.000461	0.00137	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—RARB—lung cancer	0.00046	0.00136	CbGpPWpGaD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—lung cancer	0.000458	0.00136	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—lung cancer	0.000456	0.00135	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—lung cancer	0.000454	0.00109	CcSEcCtD
Fluocinonide—Rash—Methotrexate—lung cancer	0.000448	0.00108	CcSEcCtD
Fluocinonide—NR3C1—Generic Transcription Pathway—NPPA—lung cancer	0.000448	0.00133	CbGpPWpGaD
Fluocinonide—Dermatitis—Methotrexate—lung cancer	0.000448	0.00107	CcSEcCtD
Fluocinonide—Headache—Methotrexate—lung cancer	0.000446	0.00107	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—ANXA1—lung cancer	0.000444	0.00132	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HNRNPA2B1—lung cancer	0.000442	0.00131	CbGpPWpGaD
Fluocinonide—Pruritus—Doxorubicin—lung cancer	0.000436	0.00105	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—FLT1—lung cancer	0.00043	0.00127	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—APP—lung cancer	0.000421	0.00125	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NOTCH3—lung cancer	0.000421	0.00125	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGF9—lung cancer	0.000417	0.00124	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—lung cancer	0.000413	0.00122	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—lung cancer	0.000407	0.000977	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—lung cancer	0.000406	0.0012	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6R—lung cancer	0.000405	0.0012	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—lung cancer	0.000405	0.0012	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—KHSRP—lung cancer	0.000404	0.0012	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JUNB—lung cancer	0.000399	0.00118	CbGpPWpGaD
Fluocinonide—Rash—Doxorubicin—lung cancer	0.000388	0.000931	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—lung cancer	0.000388	0.000931	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PIK3CG—lung cancer	0.000387	0.00115	CbGpPWpGaD
Fluocinonide—Headache—Doxorubicin—lung cancer	0.000386	0.000925	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—lung cancer	0.000374	0.00111	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—POMC—lung cancer	0.000368	0.00109	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—STK11—lung cancer	0.000362	0.00107	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6R—lung cancer	0.000359	0.00106	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EIF2B5—lung cancer	0.000353	0.00105	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FOXO3—lung cancer	0.000349	0.00104	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL6—lung cancer	0.000343	0.00102	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAP2K1—lung cancer	0.000342	0.00101	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CD—lung cancer	0.00034	0.00101	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NOTCH3—lung cancer	0.00034	0.00101	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CDKN1A—lung cancer	0.000335	0.000994	CbGpPWpGaD
Fluocinonide—Dexamethasone—PTGS2—lung cancer	0.000332	0.0182	CrCbGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—lung cancer	0.00033	0.000978	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AVP—lung cancer	0.000327	0.00097	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—JUNB—lung cancer	0.000322	0.000954	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—lung cancer	0.000321	0.000953	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—DICER1—lung cancer	0.000319	0.000947	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1R—lung cancer	0.000315	0.000934	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HES1—lung cancer	0.00031	0.000918	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CASP3—lung cancer	0.000308	0.000912	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—RAF1—lung cancer	0.000304	0.0009	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—lung cancer	0.000302	0.000895	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—STAT3—lung cancer	0.000299	0.000887	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—JUN—lung cancer	0.000299	0.000886	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CB—lung cancer	0.000296	0.000879	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCL8—lung cancer	0.000285	0.000844	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB3—lung cancer	0.000283	0.000839	CbGpPWpGaD
Fluocinonide—Dexamethasone—ABCB1—lung cancer	0.000283	0.0155	CrCbGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—lung cancer	0.000281	0.000834	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—lung cancer	0.000279	0.000826	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SKI—lung cancer	0.000276	0.000818	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—EP300—lung cancer	0.000276	0.000817	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL2—lung cancer	0.000272	0.000807	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TERT—lung cancer	0.000271	0.000804	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGFR1—lung cancer	0.000263	0.000781	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—lung cancer	0.000261	0.000774	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HIF1A—lung cancer	0.000259	0.000769	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—APOA1—lung cancer	0.00025	0.000742	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KDR—lung cancer	0.000248	0.000735	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—APC—lung cancer	0.000228	0.000677	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CG—lung cancer	0.000228	0.000677	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KIT—lung cancer	0.000228	0.000677	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—NRAS—lung cancer	0.000228	0.000677	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGF—lung cancer	0.000226	0.00067	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—RARB—lung cancer	0.000221	0.000657	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—MAPK3—lung cancer	0.000219	0.000649	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—POMC—lung cancer	0.000218	0.000645	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NPPA—lung cancer	0.000216	0.00064	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—BRAF—lung cancer	0.000215	0.000637	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6R—lung cancer	0.000212	0.000629	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CREBBP—lung cancer	0.000212	0.000628	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IL6—lung cancer	0.000209	0.000619	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—EGFR—lung cancer	0.000208	0.000617	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAP2K1—lung cancer	0.000202	0.000599	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CD—lung cancer	0.000201	0.000596	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—KRAS—lung cancer	0.000197	0.000583	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—HSPB1—lung cancer	0.000186	0.00055	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PIK3CA—lung cancer	0.000181	0.000536	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—IL6—lung cancer	0.000181	0.000535	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MDM2—lung cancer	0.00018	0.000534	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RAF1—lung cancer	0.000179	0.000532	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—lung cancer	0.000177	0.000526	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CB—lung cancer	0.000175	0.000519	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MTOR—lung cancer	0.000175	0.000519	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—CREBBP—lung cancer	0.000171	0.000507	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL8—lung cancer	0.000168	0.000499	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—HRAS—lung cancer	0.000167	0.000496	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NOTCH3—lung cancer	0.000164	0.000485	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CASP3—lung cancer	0.000161	0.000477	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL2—lung cancer	0.000161	0.000477	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL6—lung cancer	0.00016	0.000474	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCND1—lung cancer	0.000157	0.000465	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JUN—lung cancer	0.000156	0.000464	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—JUNB—lung cancer	0.000155	0.000459	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MMP9—lung cancer	0.000152	0.000451	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1A—lung cancer	0.000152	0.00045	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTEN—lung cancer	0.000151	0.000449	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AKT1—lung cancer	0.000148	0.000438	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EP300—lung cancer	0.000144	0.000428	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SRC—lung cancer	0.00014	0.000416	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VEGFA—lung cancer	0.000137	0.000405	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—STAT3—lung cancer	0.000135	0.000401	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NRAS—lung cancer	0.000135	0.0004	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MAPK3—lung cancer	0.000129	0.000383	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—lung cancer	0.000126	0.000373	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGFR—lung cancer	0.000123	0.000365	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KRAS—lung cancer	0.000116	0.000344	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ERCC2—lung cancer	0.000112	0.000333	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PIK3CA—lung cancer	0.000107	0.000316	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—lung cancer	0.000103	0.000306	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—lung cancer	0.000101	0.000301	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HRAS—lung cancer	9.87e-05	0.000293	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL6—lung cancer	9.45e-05	0.00028	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKT1—lung cancer	8.72e-05	0.000259	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—CREBBP—lung cancer	8.23e-05	0.000244	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MAPK3—lung cancer	5.02e-05	0.000149	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—lung cancer	4.89e-05	0.000145	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—AKT1—lung cancer	3.39e-05	0.0001	CbGpPWpGaD
